Literature DB >> 15655682

[Pathogenesis of the ductal pancreatic adenocarcinoma: implications for future therapies?].

G Schneider1, R M Schmid.   

Abstract

Despite the advances in the knowledge of the molecular pathogenesis, pancreatic cancer remains a devastating disease with an 5-year survival rate below 5%. Current therapeutic approaches are not successful in respect to overall survival. There is a need to transfer the knowledge of basic science to new therapeutic strategies. This review describes the disturbed cell cycle control, anti-apoptotic mechanisms, the process of invasion and metastasis and angioneogenesis of pancreatic cancer cells. This knowledge will allow the development of novel therapeutic strategies for the future.

Entities:  

Mesh:

Year:  2005        PMID: 15655682     DOI: 10.1007/s00108-004-1330-4

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  30 in total

Review 1.  The phosphatidylinositol 3-Kinase AKT pathway in human cancer.

Authors:  Igor Vivanco; Charles L Sawyers
Journal:  Nat Rev Cancer       Date:  2002-07       Impact factor: 60.716

Review 2.  Death and anti-death: tumour resistance to apoptosis.

Authors:  Frederik H Igney; Peter H Krammer
Journal:  Nat Rev Cancer       Date:  2002-04       Impact factor: 60.716

3.  Stat3 and NF-kappaB activation prevents apoptosis in pancreatic carcinogenesis.

Authors:  Florian R Greten; Christoph K Weber; Tim F Greten; Günter Schneider; Martin Wagner; Guido Adler; Roland M Schmid
Journal:  Gastroenterology       Date:  2002-12       Impact factor: 22.682

4.  Matrix metalloproteinase-7 is expressed by pancreatic cancer precursors and regulates acinar-to-ductal metaplasia in exocrine pancreas.

Authors:  Howard C Crawford; Charles R Scoggins; M Kay Washington; Lynn M Matrisian; Steven D Leach
Journal:  J Clin Invest       Date:  2002-06       Impact factor: 14.808

Review 5.  Apoptosis in cancer--implications for therapy.

Authors:  Henning Schulze-Bergkamen; Peter H Krammer
Journal:  Semin Oncol       Date:  2004-02       Impact factor: 4.929

6.  Inhibition of AKT abrogates chemotherapy-induced NF-kappaB survival mechanisms: implications for therapy in pancreatic cancer.

Authors:  Bridget N Fahy; Michael G Schlieman; Subbulakshmi Virudachalam; Richard J Bold
Journal:  J Am Coll Surg       Date:  2004-04       Impact factor: 6.113

7.  Role of Sp proteins in regulation of vascular endothelial growth factor expression and proliferation of pancreatic cancer cells.

Authors:  Maen Abdelrahim; Roger Smith; Robert Burghardt; Stephen Safe
Journal:  Cancer Res       Date:  2004-09-15       Impact factor: 12.701

8.  Mitogenic and antiapoptotic role of constitutive NF-kappaB/Rel activity in pancreatic cancer.

Authors:  Susanne Liptay; Christoph K Weber; Leopold Ludwig; Martin Wagner; Guido Adler; Roland M Schmid
Journal:  Int J Cancer       Date:  2003-07-20       Impact factor: 7.396

Review 9.  Genetic alterations in pancreatic carcinoma.

Authors:  Gunter Schneider; Roland M Schmid
Journal:  Mol Cancer       Date:  2003-01-22       Impact factor: 27.401

10.  AKT inhibition is associated with chemosensitisation in the pancreatic cancer cell line MIA-PaCa-2.

Authors:  B N Fahy; M Schlieman; S Virudachalam; R J Bold
Journal:  Br J Cancer       Date:  2003-07-21       Impact factor: 7.640

View more
  1 in total

Review 1.  [Pancreatic carcinoma].

Authors:  M P Lutz; S Pourebrahim
Journal:  Internist (Berl)       Date:  2008-09       Impact factor: 0.743

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.